ClinicalTrials.gg
Active, not recruitingNCT05951608Updated Apr 23, 2026

A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors

A Phase 1/2 interventional study of AK127 in combination with AK112 in Advanced Solid Tumors, sponsored by Akeso. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by Akeso · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
216
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

A Phase Ib/II Open-label Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of AK127 in combination with AK112 in Patients with Advanced Malignant Tumors

Read the detailed description

The study consisted of two parts. The first part, Phase Ib is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity of AK127 in combination with AK112 in adult subjects with advanced solid tumor malignancies. The part, as a dose escalation phase is to determine the maximum tolerated dose (MTD), or recommended Phase 2 dose (RP2D) for AK127 in combination with AK112, and describe Dose Limiting Toxicity (DLT).The second part, Phase II is to Evaluate the anti-tumor activity of AK127 in combination with AK112 in different tumor species cohorts.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

Akeso is the lead sponsor of 157 studies on the registry; 67 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to understand and voluntarily sign a written form (ICF), which must be signed before the specified study procedures required for the study are performed.
  2. Males or females aged ≥ 18 to ≤ 75 years at the time of signing informed consent.
  3. (ECOG) Performance Status (PS) 0 or 1.
  4. ≥3 months;
  5. or cytologically documented advanced or solid tumor that is /relapsed to standard therapies, or for which no effective standard therapy is available, or the subject is not suitable for standard therapy.
  6. Adequate organ function.
  7. Patients of must agree to use effective measures.

Exclusion criteria

Exclusion Criteria:

  1. The patient has received prior immunotherapy against TIGIT target.
  2. The patient had previously been treated with anti-PD -(L)1 and anti-VEGF targets.
  3. Currently enrolled in any other clinical study.
  4. Receipt of any anticancer therapy within 4 weeks prior to the first dose of drug;
  5. Symptomatic central nervous system .
  6. Active within the past 3 years, with the exception of tumors in this study and cured local tumors
  7. Active disease requiring systemic treatment prior to the start of study treatment.
  8. There is a history of major diseases 1 year prior to the first dose.
  9. Medical history of gastrointestinal perforation or gastrointestinal fistula within 6 months prior to the first dose
  10. Received chest radiation therapy prior to the first dose
  11. Presence of clinically symptomatic pleural effusion, pericardial effusion, or ascites requiring frequent drainage.
  12. Active or previously documented inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis).
  13. Receipt of live or attenuated vaccination within 4 weeks prior to the first dose of Investigational drug.
  14. Known history of testing positive for (HIV) or known acquired immunodeficiency syndrome (AIDS).
  15. Known history of active tuberculosis.
  16. History of organ transplant or hematopoietic stem cell.
  17. History of primary immunodeficiency.
  18. Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results.
  19. Other cases deemed inappropriate by the investigator.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
216 participants (estimated)

Study arms

  • Experimental
    AK127 in combination with AK112

    Subjects will receive AK127 in combination with AK112 by intravenous administration

    Drug: AK127 in combination with AK112

Interventions

  • DrugAK127 in combination with AK112

    Drug pages: Lancastotug · Ivonescimab

    AK127 in combination with AK112 (administered on Day 1 of each cycle, Q3W) up to 2 years

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs)

    An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment

    Time frame: From the subject signs the ICF to 30 days (AE) and 90 days (SAE) after the last dose of study treatment or initiation of other anti-tumor therapy, whichever occurs first

  2. Number of participants with a Dose Limiting Toxicity (DLT)

    DLTs will be assessed during the first 3 weeks of treatment for dose-escalation Ib phase and are defined as toxicities that meet pre-defined severity criteria, and assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first cycle (3 weeks) of treatment

    Time frame: During the first 3 weeks

  3. Number of participants with ORR

    Efficacy measures such as overall response rate (ORR), which is the proportion of subjects with CR or PR by investigator based on RECIST v1.1

    Time frame: Up to 2 years

  4. Progression-Free Survival

    PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first assessed by investigator Per RECIST 1.1.

    Time frame: Up to 2 years

Secondary outcomes

  1. Disease control rate

    DCR, which is defined as the proportion of subjects with CR, PR, or SD, based on RECIST v1.1

    Time frame: Up to 2 years

  2. Duration of response

    DoR, which is defined as the duration from the first documentation of objective response to the first documented disease progression or death due to any cause, whichever occurs first.

    Time frame: Up to 2 years

  3. Time to Progress

    TTR is defined as the time to response base on RECIST v1.1

    Time frame: Up to 2 years

  4. AUC of AK127 and AK112

    Area under the curve (AUC) of AK127 and AK112

    Time frame: Up to 2 years

  5. PK of AK127 and AK112

    The endpoints for assessment of PK of AK127 and AK112 include serum concentrations of AK127 and AK112 at different timepoints after AK127 and AK112 administration

    Time frame: Up to 2 years

  6. Cmax of AK127 and AK112

    Maximum observed concentration (Cmax) of AK127 and AK112

    Time frame: Up to 2 years

  7. Cmin of AK127 and AK112 at steady state

    Minimum observed concentration (Cmin) of AK127 and AK112 at steady state

    Time frame: Up to 2 years

  8. The immunogenicity of AK127 and AK112

    The immunogenicity of AK127 and AK112 will be assessed by summarizing the number of subjects who develop detectable anti-drug antibodies (ADAs)

    Time frame: Up to 2 years

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2023 (actual). Primary completion is estimated for May 2026, 30 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2023
First posted
Jul 19, 2023
StartActual
Oct 16, 2023
Primary completionEst.
May 1, 2026
CompletionEst.
Aug 15, 2026
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05951608
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Jul 19, 2023
Start date
Oct 16, 2023
Primary completion
May 1, 2026 (estimated)
Completion
Aug 15, 2026 (estimated)
Last update
Apr 23, 2026

Study contacts

shun lu, MD
principal investigator · Shanghai Chest Hospital
yun fan, MD
principal investigator · Zhejiang Cancer Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lancastotug · Ivonescimab

Start the discussion